Acuity Begins Second Phase II Trial, This Time in Macular Edema; AMD Trial Completes Patient Dosing | GenomeWeb

Acuity Pharmaceuticals announced last week that it has begun testing its siRNA drug Cand5 in a pilot phase II trial for diabetic macular edema, and that it has also completed patient dosing of the drug in its phase II trial for age-related macular degeneration.

The company said that the DME study is expected to wrap up by the end of 2006, while data from the AMD trial are expected by mid-year. A phase III trial of Cand5 in AMD is expected to begin sometime in 2007.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

In Nature this week: genetic history of HIV in the US, and more.